24 completed, 13 recruiting, 7 active not recruiting, 4 not yet recruiting. 14 Phase 3, 13 Phase 4, 10 Phase 2, 3 Not applicable, 3 Phase 1.
Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial Faricimab, Sham - Central Serous Chorioretinopathy (CSC) | Phase 2 | Not yet recruiting | Singapore National Eye Centre | 50 | 2026-12-01 | 2026-07-02 |
| Anti-VEGF Versus Prompt Laser or Observation for Proliferative Sickle Cell Retinopathy (ALPS) Faricimab Injection for stage 3 or stage 4 Proliferative sickle cell eyes, Vitrectomy, Laser photocoagulation - Proliferative Sickle Cell Retinopathy | Phase 3 | Not yet recruiting | University of Illinois Chicago | 50 | 2026-12-01 | 2026-11-06 |
| South Asian Patients With Diabetic Macular Oedema Treated With Faricimab Assessing the Efficacy, Durability, and Safety (SEAFAR Study) Intravitreal anti-VEGF injection, Faricimab - Diabetic Macular Edema | Phase 4 | Not yet recruiting | Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust | 120 | 2026-11-01 | 2026-08-07 |
| A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome Faricimab Injection [Vabysmo] - Presumed Ocular Histoplasmosis | Phase 4 | Recruiting | Cincinnati Eye Institute, Southwest Ohio | 25 | 2026-07-01 | 2026-07-10 |
| Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration | Phase 4 | Recruiting | Junyeop Lee | 64 | 2026-06-29 | 2026-07-27 |
| Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material Vabysmo 6 MG in 0.05 ML Injection - Macular Degeneration, Age Related | Phase 4 | Recruiting | Biobizkaia Health Research Institute | 100 | 2026-05-25 | 2026-05-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) RO7823653, Faricimab - Diabetic Macular Edema | Phase 1 | Recruiting | Genentech, Inc. | 93 | 2026-04-21 | 2026-11-09 |
| Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab Faricimab, Biosimilar ranibizumab - Diabetic Retinopathy (DR), Diabetic Macular Edema (DME) | Not applicable | Recruiting | Osijek University Hospital | 100 | 2026-03-12 | 2026-04-09 |
| Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy (PCV), Age Related Macular Degeneration | Phase 3 | Recruiting | Yeungnam University College of Medicine | 50 | 2026-03-01 | 2026-03-10 |
| Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration Faricimab - Neovascular Age-related Macular Degeneration(nAMD) | Not yet recruiting | Hui Peng | 35 | 2025-09-01 | 2025-07-28 | |
| Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration Faricimab Injection [Vabysmo] - Macular Degeneration Choroidal Neovascularization | Phase 4 | Recruiting | Hospital Authority, Hong Kong | 40 | 2025-08-21 | 2025-10-01 |
| Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) Faricimab Injection [Vabysmo] - Polypoidal Choroidal Vasculopathy | Phase 4 | Recruiting | Association for Innovation and Biomedical Research on Light and Image | 120 | 2025-08-06 | 2026-02-06 |
| Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR Vitrectomy, Endolaser, Faricimab - Proliferative Diabetic Retinopathy (PDR) | Phase 3 | Recruiting | Jaeb Center for Health Research | 426 | 2025-08-04 | 2026-09-18 |
| Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting Faricimab, Ranibizumab - Age Related Macular Degeneration | Not applicable | Recruiting | Singapore National Eye Centre | 117 | 2025-07-18 | 2026-09-16 |
| A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME） IBI302, Faricimab - Diabetic Macular Oedema | Phase 2 | Active not recruiting | Innovent Biologics Technology Limited (Shanghai R&D Center) | 150 | 2025-04-24 | 2026-05-27 |
| A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration Faricimab - Neovascular Age-related Macular Degeneration (nAMD) | Phase 4 | Active not recruiting | Hoffmann-La Roche | 274 | 2025-03-14 | 2026-10-27 |
| A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 Faricimab, OLN324 - Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration | Phase 1 | Completed | Ollin Biosciences, Inc. | 164 | 2025-02-12 | 2026-03-19 |
| A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) Faricimab - Neovascular Age-related Macular Degeneration, Diabetic Macular Edema | Active not recruiting | Hoffmann-La Roche | 875 | 2025-02-05 | 2026-10-02 | |
| Epivascular Glia Regression and Macular Pigment Restoration After Faricimab in Diabetic Retinopathy Faricimab Injection [Vabysmo], Aflibercept (2.0 mg) - Diabetic Retinopathy, DR | Completed | Federico II University | 60 | 2025-01-01 | 2026-04-13 | |
| Biological Changes in Fibrovascular Membranes of Patients With Proliferative Diabetic Retinopathy Following Faricimab Injection conbercept ophthalmic injection （0.5mg）, Faricimab - Proliferative Diabetic Retinopathy | Not applicable | Completed | Bojie Hu | 8 | 2024-12-01 | 2025-08-28 |
Showing 20 of 51. Sign in to see all of them.
Macular Degeneration (9) · Retinal Vein Occlusion (5) · Choroidal Neovascularization (3) · Diabetic Retinopathy (3) · Macular Edema (2) · Polypoidal Choroidal Vasculopathy (2) · Wet Macular Degeneration (2) · Central Serous Chorioretinopathy (1) · Glycogen Storage Disease Type II (1) · Uveitis (1) · Vision Disorders (1)
Hoffmann-La Roche (17) · Copenhagen University Hospital, Rigshospitalet (4) · Genentech, Inc. (3) · Jaeb Center for Health Research (2) · Singapore National Eye Centre (2) · Association for Innovation and Biomedical Research on Light and Image (1) · Biobizkaia Health Research Institute (1) · Birmingham and Midland Eye Centre Sandwell and west Birmingham NHS trust (1) · Bojie Hu (1) · Cincinnati Eye Institute, Southwest Ohio (1) · Faculty Hospital Kralovske Vinohrady (1) · Federico II University (1) · Greater Houston Retina Research (1) · Hospital Authority, Hong Kong (1) · Hui Peng (1)
United States (25) · Italy (14) · Spain (13) · Germany (12) · Poland (12) · China (11) · France (11) · South Korea (11) · United Kingdom (11) · Australia (10) · Singapore (10) · Denmark (9) · Hong Kong (9) · Hungary (9) · Taiwan (9)
Miklos Schneider, MD, PhD (3) · Andreas Wedrich, MD (1) · Bushra Mushtaq, FRCS (1) · Dr. Varun Chaudhary, MD, FRCS(C) (1) · Duaa J Kadhim (1) · Jean-Baptiste Ducloyer, M.D (1) · Junyeop Lee, PhD (1) · Katja Hatz, MD (1) · Martin Pencak, MD (1) · Panpan Ye, doctor (1) · Yann Maucourant, M.D (1)
PMID 38758639, PMID 41534798, PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36897413, PMID 37294433, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38852921, PMID 40668667, PMID 41712218, PMID 42753135, PMID 42771326, PMID 21438852, PMID 30905643, PMID 32729888, PMID 32729897, PMID 34201045, PMID 36912792, PMID 37021018, PMID 37422192, PMID 37868796, PMID 37955955, PMID 38416237, PMID 39580145, PMID 40107501, PMID 40496217, PMID 40886069, PMID 41587134, PMID 41961203, PMID 42005909, PMID 42054086, PMID 42058170, PMID 42105126, PMID 42141825, PMID 42622958
2017 (2), 2018 (2), 2023 (2), UG1EY014231 (2)